about
3D quantitative assessment of response to fractionated stereotactic radiotherapy and single-session stereotactic radiosurgery of vestibular schwannoma.Torus palatinus.Resistance of glioblastoma-initiating cells to radiation mediated by the tumor microenvironment can be abolished by inhibiting transforming growth factor-β.Imaging and extent of surgical resection predict risk of meningioma recurrence better than WHO histopathological gradeStereotactic body radiation therapy in pancreatic cancer: the new frontier.Antiangiogenic Therapies and Extracranial Metastasis in Glioblastoma: A Case Report and Review of the Literature.Benign meningiomas (WHO Grade I) with atypical histological features: correlation of histopathological features with clinical outcomes.Development of a novel multiplexed assay for quantification of transforming growth factor-β (TGF-β).LAG3 (CD223) as a cancer immunotherapy target.Long-term Treatment Response and Patient Outcomes for Vestibular Schwannoma Patients Treated with Hypofractionated Stereotactic Radiotherapy.Is there a role for an external beam boost in cervical cancer radiotherapy?Introduction to the medical professions through an innovative medical student-run pipeline program.Avelumab demonstrates promise in advanced NSCLC.Stereotactic Radiotherapy Increases Functionally Suppressive Regulatory T Cells in the Tumor Microenvironment.Incorporating Radiation Oncology into Immunotherapy: proceedings from the ASTRO-SITC-NCI immunotherapy workshop.Concurrent Immune Checkpoint Inhibitors and Stereotactic Radiosurgery for Brain Metastases in Non-Small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma.Elective Nodal Irradiation Attenuates the Combinatorial Efficacy of Stereotactic Radiation Therapy and ImmunotherapyWhite paper on microbial anti-cancer therapy and preventionRole of noninvasive molecular imaging in determining responseEffects of perineural invasion on biochemical recurrence and prostate cancer-specific survival in patients treated with definitive external beam radiotherapyTNFα and Radioresistant Stromal Cells Are Essential for Therapeutic Efficacy of Cyclic Dinucleotide STING Agonists in Nonimmunogenic Tumors.Targeting the Tumor Microenvironment with Immunotherapy for Genitourinary MalignanciesAvelumab: is it time to get excited?Atypical Histopathological Features and the Risk of Treatment Failure in Nonmalignant Meningiomas: A Multi-Institutional AnalysisThe Winds of Change: Emerging Therapeutics in Prostate CancerImmunomodulatory Effects of Stereotactic Body Radiation Therapy: Preclinical Insights and Clinical Opportunities
P50
Q30389621-51732F35-1B22-482B-88C9-0FA49E68EC09Q33763069-7A8546C4-706A-40D9-8407-EC0F9FE0A91DQ36511945-2B44BFA6-5224-4815-B5A4-7010C923AE80Q36893234-359B4533-031A-47E4-BB7A-82763C14E4A1Q38245676-D2E51802-4972-4228-AD16-5B4CA9C813A0Q38551868-F9375178-C07A-487A-88AC-475E35F6D924Q38566832-E72178BE-2A67-4D59-8D1F-5B0F2E8349FAQ38920213-318E41B5-2E08-468C-93E0-3974B0AAA1E3Q39160974-4B89EB4F-9A19-481C-B5BC-34D76B4A1164Q41475794-391D4EA7-E17E-45BC-9AA1-98968C811607Q43069022-D565995B-B076-4EC5-87CC-EBB629013E30Q44240295-550FD4C1-370D-491E-88F2-C5D5A3895FFBQ47111602-8D677E05-5BFA-49BA-B0C4-BE8B93AFCC00Q47880159-5944360F-22B5-4F86-A8D3-B9465E1F4B7CQ49571153-F51512B3-90A6-4F70-B548-4B02522B87B4Q52683617-118AF5A1-99C7-4FF2-8298-6B4FF12673BCQ56891895-5D1B2108-D633-4935-A72F-4530A29634CFQ56898750-2D562B25-E0D9-4673-8608-60E457BFA346Q58119177-526184BA-D0EA-48A9-B922-94AAD036E11BQ62616404-030A5575-161D-4EAA-A15E-B698028E0238Q64989143-758F127D-53A2-4EC5-83BE-FBCD5FD4FCD1Q88008385-2F7CADE5-9AAB-4174-B714-00AF71987E21Q89231103-25B580F3-8C1B-4D6C-835F-99AC78918F0AQ90668498-E416909B-1BE4-428E-8FA4-9D7CB88D2FB4Q91546850-4E47DFAC-05DE-4D6C-8566-ECC8401FB2ADQ92143135-63D631C6-5018-4CB6-B024-CA0D39BC1ACF
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Ariel E. Marciscano
@ast
Ariel E. Marciscano
@en
Ariel E. Marciscano
@es
Ariel E. Marciscano
@nl
Ariel E. Marciscano
@sl
type
label
Ariel E. Marciscano
@ast
Ariel E. Marciscano
@en
Ariel E. Marciscano
@es
Ariel E. Marciscano
@nl
Ariel E. Marciscano
@sl
prefLabel
Ariel E. Marciscano
@ast
Ariel E. Marciscano
@en
Ariel E. Marciscano
@es
Ariel E. Marciscano
@nl
Ariel E. Marciscano
@sl
P106
P1153
54879389700
P31
P496
0000-0001-8838-2127